These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27345158)

  • 1. Comparison of combined low-dose hormone therapy vs. tibolone in the prevention of bone loss.
    Kalder M; Kyvernitakis I; Hars O; Kauka A; Hadji P
    Climacteric; 2016 Oct; 19(5):471-7. PubMed ID: 27345158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss.
    Roux C; Pelissier C; Fechtenbaum J; Loiseau-Peres S; Benhamou CL
    Osteoporos Int; 2002 Mar; 13(3):241-8. PubMed ID: 11991445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy.
    Dören M; Rübig A; Coelingh Bennink HJ; Holzgreve W
    Menopause; 1999; 6(4):299-306. PubMed ID: 10614676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women.
    Delmas PD; Confavreux E; Garnero P; Fardellone P; de Vernejoul MC; Cormier C; Arce JC
    Osteoporos Int; 2000; 11(2):177-87. PubMed ID: 10793878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women.
    Osmanağaoğlu MA; Osmanağaoğlu S; Osmanağaoğlu T; Okumuş B; Bozkaya H
    Fertil Steril; 2005 Aug; 84(2):384-93. PubMed ID: 16084879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women.
    Rubinacci A; Peruzzi E; Modena AB; Zanardi E; Andrei B; De Leo V; Pansini FS; Quebe-Fehling E; de Palacios PI
    Menopause; 2003; 10(3):241-9. PubMed ID: 12792297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women.
    Prelevic GM; Bartram C; Wood J; Okolo S; Ginsburg J
    Gynecol Endocrinol; 1996 Dec; 10(6):413-20. PubMed ID: 9032569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction.
    Nijland EA; Nathorst-Böös J; Palacios S; van de Weijer PW; Davis S; Stathopoulos VM; Birkhaeuser MH; von Mauw E; Mulder RJ; Schultz WC;
    Climacteric; 2009 Apr; 12(2):114-21. PubMed ID: 19177255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
    BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.
    Lundström E; Christow A; Kersemaekers W; Svane G; Azavedo E; Söderqvist G; Mol-Arts M; Barkfeldt J; von Schoultz B
    Am J Obstet Gynecol; 2002 Apr; 186(4):717-22. PubMed ID: 11967497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact of tibolone compared with continuous-combined hormone replacement therapy. In the management of postmenopausal women with climacteric symptoms in the UK.
    Plumb JM; Guest JF
    Pharmacoeconomics; 2000 Nov; 18(5):477-86. PubMed ID: 11151401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies.
    Gallagher JC; Baylink DJ; Freeman R; McClung M
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4717-26. PubMed ID: 11600531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in body composition during post-menopausal hormone therapy: a 2 year prospective study.
    Arabi A; Garnero P; Porcher R; Pelissier C; Benhamou CL; Roux C
    Hum Reprod; 2003 Aug; 18(8):1747-52. PubMed ID: 12871894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial.
    Nijland EA; Weijmar Schultz WC; Nathorst-Boös J; Helmond FA; Van Lunsen RH; Palacios S; Norman RJ; Mulder RJ; Davis SR;
    J Sex Med; 2008 Mar; 5(3):646-56. PubMed ID: 18304284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
    Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
    Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tibolone and combined 17beta-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial.
    Garnero P; Jamin C; Benhamou CL; Pelissier C; Roux C
    Hum Reprod; 2002 Oct; 17(10):2748-53. PubMed ID: 12351557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study.
    Polisseni AF; Andrade AT; Ribeiro LC; Castro IQ; Brandão M; Polisseni F; Guerra Mde O
    Maturitas; 2013 Feb; 74(2):172-8. PubMed ID: 23201326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.